C07K 2317/32
Specific for a neo-epitope on a complex
Official title: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
C07K2317/32 (Specific for a neo-epitope on a complex) appears on 492 US grants and 943 published applications in this corpus.
Search patents in C07K- Granted patents
- 492
- Published applications
- 943
- Assignees
- 397
- Inventors
- 1,845
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 3 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 6 |
| 2003 | 1 | 8 |
| 2004 | 1 | 9 |
| 2005 | 2 | 5 |
| 2006 | 3 | 10 |
| 2007 | 4 | 14 |
| 2008 | 8 | 13 |
| 2009 | 9 | 14 |
| 2010 | 9 | 21 |
| 2011 | 10 | 33 |
| 2012 | 15 | 33 |
| 2013 | 23 | 31 |
| 2014 | 15 | 30 |
| 2015 | 23 | 36 |
| 2016 | 18 | 34 |
| 2017 | 31 | 39 |
| 2018 | 17 | 61 |
| 2019 | 19 | 78 |
| 2020 | 44 | 72 |
| 2021 | 46 | 80 |
| 2022 | 35 | 76 |
| 2023 | 38 | 62 |
| 2024 | 51 | 78 |
| 2025 | 45 | 62 |
| 2026 | 20 | 37 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Methods for predicting cancer drug responsiveness22 Sep 2026US 12,742,764 B2Eutropics Pharmaceuticals, Inc.
- Methods of treating paraproteinemic neuropathy with anti-C2 antibodies18 Aug 2026US 12,708,664 B2argenx BV
- Stable aqueous anti-TFPI antibody formulation18 Aug 2026US 12,708,668 B2Pfizer Inc.
- Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy16 Jun 2026US 12,653,872 B2AC Immune SA
- Modified antibodies and uses thereof17 Sep 2026US 2026/0274934 A1Gat Biosciences, S.L.
- Human fcrn-binding modified antibodies and methods of use17 Sep 2026US 2026/0274936 A1Hoffmann-La Roche Inc.
- Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof17 Sep 2026US 2026/0274962 A1Regeneron Pharmaceuticals, Inc.
- Fusion neoantigens for use in cancer vaccines, antibody therapy, and cell therapies27 Aug 2026US 2026/0250358 A1The Cleveland Clinic Foundation
- Tcr molecule targeting kras g12v mutation, cell, and uses thereof27 Aug 2026US 2026/0250388 A1Beijing Dcty Biotech Co., Ltd.
Most cited
By later US patents
- Tissue factor compositions and ligands for the specific coagulation of vasculature156US 5,877,289 ABoard of Regents, The University of Texas System · 1999
- Human antibodies specific for interleukin 15 (IL-15)72US 7,153,507 B2Genmab A/S · 2006
- Mammalian cytokines; related reagents and methods52US 7,090,847 B1Schering Corporation · 2006
- Non-naturally occurring T cell receptors50US 8,519,100 B2Immunocore Limited · 2013
- Neutralizing antibodies and methods of use thereof48US 8,609,822 B2NovImmune S.A. · 2013